[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100528742":3},{"organization":4,"armGroups":7,"interventions":41,"overallOfficials":47,"centralContacts":48,"locations":54,"responsibleParty":246,"collaborators":47,"id":248,"slug":47,"hasResults":249,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":47,"eligibilityCriteria":253,"healthyVolunteers":249,"sex":254,"minAge":255,"maxAge":256,"enrollmentInfo":257,"targetDuration":47,"studyType":260,"phases":261,"briefSummary":263,"conditions":264,"keywords":267,"overallStatus":57,"whyStopped":47,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":283},{"fullName":5,"class":6},"Verve Therapeutics, Inc.","INDUSTRY",[8,14,17,20,23,26,29,32,35,38],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1: Single Ascending Dose Escalation","EXPERIMENTAL","Participants will receive a single dose of VERVE-102.",[13],"Drug: VERVE-102",{"label":15,"type":10,"description":11,"interventionNames":16},"Cohort 2: Single Ascending Dose Escalation",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"Cohort 3: Single Ascending Dose Escalation",[13],{"label":21,"type":10,"description":11,"interventionNames":22},"Cohort 4: Single Ascending Dose Escalation",[13],{"label":24,"type":10,"description":11,"interventionNames":25},"Cohort 5: Single Ascending Dose Escalation",[13],{"label":27,"type":10,"description":11,"interventionNames":28},"Cohort 6: Single Ascending Dose Escalation",[13],{"label":30,"type":10,"description":11,"interventionNames":31},"Cohort 7: Single Ascending Dose Escalation",[13],{"label":33,"type":10,"description":11,"interventionNames":34},"Cohort 8: Single Ascending Dose Escalation",[13],{"label":36,"type":10,"description":11,"interventionNames":37},"Cohort 9: Single Fixed Dose",[13],{"label":39,"type":10,"description":11,"interventionNames":40},"Cohort 10: Single Fixed Dose",[13],[42],{"type":43,"name":44,"description":45,"armGroupLabels":46,"otherNames":47},"DRUG","VERVE-102","Intravenous (IV) infusion",[39,9,15,18,21,24,27,30,33,36],null,[49],{"name":50,"role":51,"phone":52,"phoneExt":47,"email":53},"Clinical Development","CONTACT","781-970-6833","verve102clinicaltrials@lists.lilly.com",[55,68,77,86,94,102,111,120,129,137,144,151,159,166,173,180,187,194,202,210,218,225,232,239],{"facility":56,"status":57,"city":58,"state":59,"zip":60,"country":61,"cosmosGeoPoint":62,"geoPoint":67,"contacts":47},"Clinical Study Center","RECRUITING","Dothan","Alabama","36305","United States",{"type":63,"coordinates":64},"Point",[65,66],-85.39049,31.22323,{"lat":66,"lon":65},{"facility":56,"status":57,"city":69,"state":70,"zip":71,"country":61,"cosmosGeoPoint":72,"geoPoint":76,"contacts":47},"Pomona","California","91768",{"type":63,"coordinates":73},[74,75],-117.75228,34.05529,{"lat":75,"lon":74},{"facility":56,"status":57,"city":78,"state":79,"zip":80,"country":61,"cosmosGeoPoint":81,"geoPoint":85,"contacts":47},"Boca Raton","Florida","33434",{"type":63,"coordinates":82},[83,84],-80.0831,26.35869,{"lat":84,"lon":83},{"facility":56,"status":57,"city":87,"state":79,"zip":88,"country":61,"cosmosGeoPoint":89,"geoPoint":93,"contacts":47},"Jacksonville","32216",{"type":63,"coordinates":90},[91,92],-81.65565,30.33218,{"lat":92,"lon":91},{"facility":56,"status":57,"city":95,"state":79,"zip":96,"country":61,"cosmosGeoPoint":97,"geoPoint":101,"contacts":47},"Winter Park","32789",{"type":63,"coordinates":98},[99,100],-81.33924,28.6,{"lat":100,"lon":99},{"facility":56,"status":57,"city":103,"state":104,"zip":105,"country":61,"cosmosGeoPoint":106,"geoPoint":110,"contacts":47},"High Point","North Carolina","27260",{"type":63,"coordinates":107},[108,109],-80.00532,35.95569,{"lat":109,"lon":108},{"facility":56,"status":57,"city":112,"state":113,"zip":114,"country":61,"cosmosGeoPoint":115,"geoPoint":119,"contacts":47},"DeSoto","Texas","75115",{"type":63,"coordinates":116},[117,118],-96.85695,32.58986,{"lat":118,"lon":117},{"facility":56,"status":57,"city":121,"state":122,"zip":123,"country":61,"cosmosGeoPoint":124,"geoPoint":128,"contacts":47},"Renton","Washington","98057",{"type":63,"coordinates":125},[126,127],-122.21707,47.48288,{"lat":127,"lon":126},{"facility":56,"status":57,"city":130,"state":47,"zip":47,"country":131,"cosmosGeoPoint":132,"geoPoint":136,"contacts":47},"Adelaide","Australia",{"type":63,"coordinates":133},[134,135],138.59863,-34.92866,{"lat":135,"lon":134},{"facility":56,"status":57,"city":138,"state":47,"zip":47,"country":131,"cosmosGeoPoint":139,"geoPoint":143,"contacts":47},"Melbourne",{"type":63,"coordinates":140},[141,142],144.96332,-37.814,{"lat":142,"lon":141},{"facility":56,"status":57,"city":145,"state":47,"zip":47,"country":131,"cosmosGeoPoint":146,"geoPoint":150,"contacts":47},"Sydney",{"type":63,"coordinates":147},[148,149],151.20732,-33.86785,{"lat":149,"lon":148},{"facility":56,"status":57,"city":152,"state":47,"zip":47,"country":153,"cosmosGeoPoint":154,"geoPoint":158,"contacts":47},"Chicoutimi","Canada",{"type":63,"coordinates":155},[156,157],-71.06369,48.41963,{"lat":157,"lon":156},{"facility":56,"status":57,"city":160,"state":47,"zip":47,"country":153,"cosmosGeoPoint":161,"geoPoint":165,"contacts":47},"Hamilton",{"type":63,"coordinates":162},[163,164],-79.84963,43.25011,{"lat":164,"lon":163},{"facility":56,"status":57,"city":167,"state":47,"zip":47,"country":153,"cosmosGeoPoint":168,"geoPoint":172,"contacts":47},"Montreal",{"type":63,"coordinates":169},[170,171],-73.58781,45.50884,{"lat":171,"lon":170},{"facility":56,"status":57,"city":174,"state":47,"zip":47,"country":153,"cosmosGeoPoint":175,"geoPoint":179,"contacts":47},"Québec",{"type":63,"coordinates":176},[177,178],-71.21454,46.81228,{"lat":178,"lon":177},{"facility":56,"status":57,"city":181,"state":47,"zip":47,"country":153,"cosmosGeoPoint":182,"geoPoint":186,"contacts":47},"Toronto",{"type":63,"coordinates":183},[184,185],-79.39864,43.70643,{"lat":185,"lon":184},{"facility":56,"status":57,"city":188,"state":47,"zip":47,"country":153,"cosmosGeoPoint":189,"geoPoint":193,"contacts":47},"Vancouver",{"type":63,"coordinates":190},[191,192],-123.11934,49.24966,{"lat":192,"lon":191},{"facility":56,"status":57,"city":195,"state":47,"zip":47,"country":196,"cosmosGeoPoint":197,"geoPoint":201,"contacts":47},"Rehovot","Israel",{"type":63,"coordinates":198},[199,200],34.81199,31.89421,{"lat":200,"lon":199},{"facility":56,"status":57,"city":203,"state":47,"zip":47,"country":204,"cosmosGeoPoint":205,"geoPoint":209,"contacts":47},"Christchurch","New Zealand",{"type":63,"coordinates":206},[207,208],172.63333,-43.53333,{"lat":208,"lon":207},{"facility":56,"status":57,"city":211,"state":47,"zip":47,"country":212,"cosmosGeoPoint":213,"geoPoint":217,"contacts":47},"Birmingham","United Kingdom",{"type":63,"coordinates":214},[215,216],-1.89983,52.48142,{"lat":216,"lon":215},{"facility":56,"status":57,"city":219,"state":47,"zip":47,"country":212,"cosmosGeoPoint":220,"geoPoint":224,"contacts":47},"Edinburgh",{"type":63,"coordinates":221},[222,223],-3.19648,55.95206,{"lat":223,"lon":222},{"facility":56,"status":57,"city":226,"state":47,"zip":47,"country":212,"cosmosGeoPoint":227,"geoPoint":231,"contacts":47},"London",{"type":63,"coordinates":228},[229,230],-0.12574,51.50853,{"lat":230,"lon":229},{"facility":56,"status":57,"city":233,"state":47,"zip":47,"country":212,"cosmosGeoPoint":234,"geoPoint":238,"contacts":47},"Manchester",{"type":63,"coordinates":235},[236,237],-2.23743,53.48095,{"lat":237,"lon":236},{"facility":56,"status":57,"city":240,"state":47,"zip":47,"country":212,"cosmosGeoPoint":241,"geoPoint":245,"contacts":47},"Nottingham",{"type":63,"coordinates":242},[243,244],-1.15047,52.9536,{"lat":244,"lon":243},{"type":247,"investigatorFullName":47,"investigatorTitle":47,"investigatorAffiliation":47,"oldNameTitle":47,"oldOrganization":47},"SPONSOR","100528742",false,"NCT06164730","A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease","Open-label, Phase 1b, Single Ascending Dose Study to Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia or Premature Coronary Artery Disease Who Require Additional Lowering of Low-density Lipoprotein Cholesterol","Inclusion Criteria:\n\n* Diagnosis of HeFH or premature CAD\n\nExclusion Criteria:\n\n* Homozygous familial hypercholesterolemia\n* Active or history of chronic liver disease\n* Current treatment with PCSK9 inhibitor or prior treatment within specified timeframe\n* Clinically significant or abnormal laboratory values as defined by the protocol","ALL","18 Years","70 Years",{"count":258,"type":259},85,"ESTIMATED","INTERVENTIONAL",[262],"PHASE1","VT-10201 is an Open-label, Phase 1b, Single-ascending Dose Study That Will Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia (HeFH) or Premature Coronary Artery Disease (CAD) Who Require Additional Lowering of LDL-C. VERVE-102 Uses Base-editing Technology Designed to Disrupt the Expression of the PCSK9 Gene in the Liver and Lower Circulating PCSK9 and LDL-C. This Study is Designed to Determine the Safety and Pharmacodynamic Profile of VERVE-102 in This Patient Population.",[265,266],"Heterozygous Familial Hypercholesterolemia","Premature Coronary Heart Disease",[44,268,269,270,271,272,273],"Familial Hypercholesterolemia","Coronary Artery Disease","Dose Escalation","Gene Editing","Base Editing","heart-2","2026-06-26",{"date":276,"type":277},"2026-06-29","ACTUAL",{"date":279,"type":277},"2024-04-30",{"date":281,"type":259},"2027-08",{"name":5,"class":6},24]